SAB Biotherapeutics Dirección
Dirección controles de criterios 4/4
El CEO de SAB Biotherapeutics es Samuel Reich , nombrado en Jan 2024, tiene una permanencia de menos de un año. compensación anual total es $768.40K, compuesta por 45.5% salario y 54.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.24% de las acciones de la empresa, por valor de $67.01K. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 4.4 años, respectivamente.
Información clave
Samuel Reich
Chief Executive Officer (CEO)
US$768.4k
Compensación total
| Porcentaje del salario del CEO | 45.5% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 2.5yrs |
| Promedio de permanencia en la Junta Directiva | 4.4yrs |
Actualizaciones recientes de la dirección
Recent updates
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
Sep 22
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$768k | US$350k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$985k | US$350k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$22m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$3m | US$53k | -US$17m |
Compensación vs. Mercado: La compensación total ($USD768.40K) de Samuel está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD652.28K).
Compensación vs. Ingresos: La compensación de Samuel ha sido consistente con los resultados de la empresa en el último año.
CEO
Samuel Reich (49 yo)
less than a year
Permanencia
US$768,396
Compensación
Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and serves as its Executive Chairman since October 22, 2021 and serves as its Director since November 2020. Samuel J. Reich has...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Chairman | less than a year | US$768.40k | 0.24% $ 67.0k | |
| Co-Founder | 10.8yrs | US$807.76k | 5.67% $ 1.6m | |
| Co-Founder & Independent Director | no data | US$25.00k | 5.63% $ 1.6m | |
| Executive VP & COO | 2.5yrs | US$549.32k | 1.08% $ 305.2k | |
| Executive VP & Chief Medical Officer | 2.4yrs | US$921.58k | 0% $ 0 | |
| Co-Founder & Board Observer | no data | sin datos | 3.15% $ 890.2k | |
| Senior Vice President of Regulatory Affairs | 3.4yrs | sin datos | sin datos |
2.5yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SABS se considera experimentado (2.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Chairman | 4yrs | US$768.40k | 0.24% $ 67.0k | |
| Co-Founder | no data | US$807.76k | 5.67% $ 1.6m | |
| Co-Founder & Independent Director | 10.8yrs | US$25.00k | 5.63% $ 1.6m | |
| Co-Founder & Board Observer | 3.1yrs | sin datos | 3.15% $ 890.2k | |
| Independent Director | 5.8yrs | US$25.00k | 0% $ 0 | |
| Independent Director | 4yrs | US$25.00k | 0.43% $ 120.9k | |
| Independent Vice Chairman | 6.8yrs | US$25.00k | 0.062% $ 17.5k | |
| Independent Director | 1.6yrs | US$26.93k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Clinical Advisory Board & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board & Member of Clinical Advisory Board | 4.8yrs | sin datos | sin datos |
4.4yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de SABS se considera experimentada (4.4 años de antigüedad promedio).